These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 15726382)

  • 21. Role of cytokine therapy in 2006 and beyond for metastatic renal cell cancer.
    Parton M; Gore M; Eisen T
    J Clin Oncol; 2006 Dec; 24(35):5584-92. PubMed ID: 17158544
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Combination therapy in metastatic renal cell cancer.
    Ravaud A; Gross-Goupil M; Bellmunt J
    Semin Oncol; 2013 Aug; 40(4):472-81. PubMed ID: 23972711
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Chemotherapy for renal cell carcinoma.
    Amato RJ
    Semin Oncol; 2000 Apr; 27(2):177-86. PubMed ID: 10768596
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Interleukin-2- and interferon alfa-2a-based immunochemotherapy in advanced renal cell carcinoma: a Prospectively Randomized Trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN).
    Atzpodien J; Kirchner H; Jonas U; Bergmann L; Schott H; Heynemann H; Fornara P; Loening SA; Roigas J; Müller SC; Bodenstein H; Pomer S; Metzner B; Rebmann U; Oberneder R; Siebels M; Wandert T; Puchberger T; Reitz M;
    J Clin Oncol; 2004 Apr; 22(7):1188-94. PubMed ID: 14981107
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sequential treatment strategies and combination therapy regimens in metastatic renal cell carcinoma.
    Pal SK; Vogelzang NJ
    Clin Adv Hematol Oncol; 2013 Mar; 11(3):146-55. PubMed ID: 23598982
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Subcutaneous interleukin-2 and interferon-alpha in metastatic renal cell carcinoma: results of a French regional experience in Languedoc.
    Culine S; Iborra F; Mottet N; Avancès C; de Graeve B; Volpé P; Vignoud J; Bringer JP; Marroncle M; Le Pellec L; Ayuso D; Jansen E; Faix A; Rebillard X
    Am J Clin Oncol; 2006 Apr; 29(2):148-52. PubMed ID: 16601433
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Bevacizumab in combination with IFN-α in metastatic renal cell carcinoma: the AVOREN trial.
    Melichar B; Procházková-Študentová H; Vitásková D
    Expert Rev Anticancer Ther; 2012 Oct; 12(10):1253-61. PubMed ID: 23136836
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Combination systemic therapy for advanced renal cell carcinoma.
    Miller RE; Larkin JM
    Oncologist; 2009 Dec; 14(12):1218-24. PubMed ID: 19939892
    [TBL] [Abstract][Full Text] [Related]  

  • 29. ICUD-EAU International Consultation on Kidney Cancer 2010: treatment of metastatic disease.
    Patard JJ; Pignot G; Escudier B; Eisen T; Bex A; Sternberg C; Rini B; Roigas J; Choueiri T; Bukowski R; Motzer R; Kirkali Z; Mulders P; Bellmunt J
    Eur Urol; 2011 Oct; 60(4):684-90. PubMed ID: 21704448
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Sorafenib reveals efficacy in sequential treatment of metastatic renal cell cancer.
    Merseburger AS; Simon A; Waalkes S; Kuczyk MA
    Expert Rev Anticancer Ther; 2009 Oct; 9(10):1429-34. PubMed ID: 19828003
    [TBL] [Abstract][Full Text] [Related]  

  • 31. New perspectives in the treatment of metastatic renal cell carcinoma.
    Barrière J; Hoch B; Ferrero JM
    Crit Rev Oncol Hematol; 2012 Dec; 84 Suppl 1():e16-23. PubMed ID: 22099727
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Interleukin-2, interferon-alpha and 5-fluorouracil immunotherapy for metastatic renal cell carcinoma: the all Ireland experience.
    O'Brien MF; Rea D; Rogers E; Bredin H; Butler M; Grainger R; McDermott TE; Mullins G; O'Brien A; Twomey A; Thornhill J
    Eur Urol; 2004 May; 45(5):613-8; discussion 619. PubMed ID: 15082204
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Progressive anemia following combination therapy with interferon-alpha and interleukin-2 in a patient with metastatic renal cell carcinoma.
    Hosokawa Y; Kishino T; Ono T; Oyama N; Hayashi K; Momose H
    Int J Urol; 2004 Oct; 11(10):906-8. PubMed ID: 15479299
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Chemotherapy of metastatic renal cancer.
    Denis L; Van Oosterom A
    Semin Surg Oncol; 1988; 4(2):91-4. PubMed ID: 3293156
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Interleukin-2, interferon-alpha and medroxyprogesterone acetate in metastatic renal cell carcinoma.
    Naglieri E; Lopez M; Lelli G; Morelli F; Amodio A; Di Tonno P; Gebbia N; Di Seri M; Chetri MC; Rizzo P; Abbate I; Casamassima A; Selvaggi FP; Colucci G
    Anticancer Res; 2002; 22(5):3045-51. PubMed ID: 12530040
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Combination therapy with capecitabine and interferon alfa-2A in patients with advanced renal cell carcinoma: a phase II study.
    Padrik P; Leppik K; Arak A
    Urol Oncol; 2004; 22(5):387-92. PubMed ID: 15464918
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma.
    Hudes G; Carducci M; Tomczak P; Dutcher J; Figlin R; Kapoor A; Staroslawska E; Sosman J; McDermott D; Bodrogi I; Kovacevic Z; Lesovoy V; Schmidt-Wolf IG; Barbarash O; Gokmen E; O'Toole T; Lustgarten S; Moore L; Motzer RJ;
    N Engl J Med; 2007 May; 356(22):2271-81. PubMed ID: 17538086
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Interleukin-2 based immunotherapy in patients with metastatic renal cell carcinoma.
    Donskov F
    Dan Med Bull; 2007 Nov; 54(4):249-65. PubMed ID: 18208677
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Adjuvant low-dose interleukin-2 (IL-2) plus interferon-α (IFN-α) in operable renal cell carcinoma (RCC): a phase III, randomized, multicentre trial of the Italian Oncology Group for Clinical Research (GOIRC).
    Passalacqua R; Caminiti C; Buti S; Porta C; Camisa R; Braglia L; Tomasello G; Vaglio A; Labianca R; Rondini E; Sabbatini R; Nastasi G; Artioli F; Prati A; Potenzoni M; Pezzuolo D; Oliva E; Alberici F; Buzio C;
    J Immunother; 2014; 37(9):440-7. PubMed ID: 25304727
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phase II clinical trial of sorafenib plus interferon-alpha treatment for patients with metastatic renal cell carcinoma in Japan.
    Eto M; Kawano Y; Hirao Y; Mita K; Arai Y; Tsukamoto T; Hashine K; Matsubara A; Fujioka T; Kimura G; Shinohara N; Tatsugami K; Hinotsu S; Naito S;
    BMC Cancer; 2015 Oct; 15():667. PubMed ID: 26452347
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.